We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Efficacy and Tolerability of AST-120 (Spherical Carbon Adsorbent) in Active Pouchitis.
- Authors
Shen, Bo; Pardi, Darrell S.; Bennett, Ana E.; Queener, Elaine; Kammer, Patricia; Hammel, Jefferey P.; LaPlaca, Caroline; Harris, M. Scott
- Abstract
OBJECTIVES:Although a majority of patients with pouchitis respond favorably to antibiotic therapy, many relapse frequently, and nonabsorbable and non-antibiotic-based agents are desirable for reducing bacterial resistance and the systemic adverse effects associated with long-term antibiotic exposure. AST-120 (a spherical carbon adsorbent) comprises highly adsorptive, porous carbon microspheres with the ability to adsorb small-molecular-weight toxins, inflammatory mediators, and harmful bile acids. The aim of this pilot trial was to evaluate the efficacy and tolerability of AST-120 in the treatment of active pouchitis.METHODS:Eligible patients were recruited from two subspecialty pouchitis clinics. Inclusion criteria were (i) ileal pouch-anal anastomosis performed for ulcerative colitis; (ii) active pouchitis with Pouchitis Disease Activity Index (PDAI) scores ≥7; and (iii) discontinuation of antibiotic therapy for at least 2 weeks. Exclusion criteria included Crohn's disease of the pouch, isolated cuffitis, pouch strictures, abscess, and sinuses. All eligible patients received AST-120 in 2-g sachets (oral) open label, thrice a day for 4 weeks. The primary efficacy end point was remission as defined by a PDAI score of <7 points; the main secondary end point was clinical response, defined by a reduction of the PDAI score of ≥3 points.RESULTS:Nineteen of 20 patients completed the trial. Eleven patients (55.0%) had a clinical response to the therapy and 10 patients (50.0%) entered remission. Median reduction in the PDAI symptom, endoscopy, and histology subscores, and PDAI total scores after 4 weeks were –2 (P=0.002), –2 (P=0.003), 0 (P=0.32), and –4 (P=0.001) points, respectively. The agent was well tolerated; one patient experienced transient mild elevation of alkaline phosphatase of uncertain significance and one patient experienced an upper respiratory infection after taking one dose of AST-120 and was excluded from the final analysis for the calculation of pre- and post-trial PDAI scores.CONCLUSIONS:AST-120 seems to be effective and well tolerated in treating patients with active pouchitis. A randomized, placebo-controlled trial is warranted for assessing the long-term efficacy and safety of AST-120 in the disease.Am J Gastroenterol 2009; 104:1468–1474; doi:10.1038/ajg.2009.138; published online 12 May 2009
- Subjects
ANTIBIOTICS; INFLAMMATORY bowel diseases; CARBON; ENDOSCOPY; CROHN'S disease
- Publication
American Journal of Gastroenterology (Springer Nature), 2009, Vol 104, Issue 6, p1468
- ISSN
0002-9270
- Publication type
Article
- DOI
10.1038/ajg.2009.138